At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QD Qudian Inc.
Pre-Market Trading 12-19 04:08:07 EST
2.54
-0.12
-4.51%
High2.69Low2.53Vol449.09K
Open2.63D1 Closing2.66Amplitude6.02%
Mkt Cap481.09MTradable Cap307.47MTotal Shares189.40M
T/O1.18MT/O Rate0.37%Tradable Shares121.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Business Wire  ·  12-11
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
GlobeNewswire  ·  12-10
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
PR Newswire  ·  12-10
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Business Wire  ·  12-09
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
GlobeNewswire  ·  12-09
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
GlobeNewswire  ·  12-07
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
GlobeNewswire  ·  12-03
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading
MT Newswires Live  ·  12-02
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
GlobeNewswire  ·  12-02
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
Qudian Up Over 22%, On Pace for Highest Close Since March 2021 -- Data Talk
Dow Jones  ·  11-27
Qudian Up Over 22%, On Pace for Highest Close Since March 2021 -- Data Talk
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
PR Newswire  ·  11-25
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Qudian Third Quarter 2024 Earnings: EPS: CN¥0.73 (vs CN¥0.84 loss in 3Q 2023)
Simply Wall St.  ·  11-24
Qudian Third Quarter 2024 Earnings: EPS: CN¥0.73 (vs CN¥0.84 loss in 3Q 2023)
Qudian: Q3 Earnings Snapshot
Associated Press Finance  ·  11-22
Qudian: Q3 Earnings Snapshot
BRIEF-Qudian Reports Third Quarter 2024 Unaudited Financial Results
Reuters  ·  11-22
BRIEF-Qudian Reports Third Quarter 2024 Unaudited Financial Results
Qudian Non-GAAP EPADS of $0.10, revenue of $7.8M
seekingalpha  ·  11-22
Qudian Non-GAAP EPADS of $0.10, revenue of $7.8M
Qudian Q3 Adj. EPADS $0.10 Up From $(0.11) YoY, Sales $7.80M Up From $4.06M YoY
Benzinga  ·  11-22
Qudian Q3 Adj. EPADS $0.10 Up From $(0.11) YoY, Sales $7.80M Up From $4.06M YoY
Qudian Q3 Income From Operations RMB -66.983 Million
THOMSON REUTERS  ·  11-22
Qudian Q3 Income From Operations RMB -66.983 Million
Qudian Incl: Qtrly Adj Net Income per Diluted Ads RMB0.71
THOMSON REUTERS  ·  11-22
Qudian Incl: Qtrly Adj Net Income per Diluted Ads RMB0.71
QD Laser Sets Profitability Goal by Fiscal Year 2027 in Mid-Term Plan
MT Newswires Live  ·  11-22
QD Laser Sets Profitability Goal by Fiscal Year 2027 in Mid-Term Plan
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
GlobeNewswire  ·  11-20
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
No data available

Introduction

Company Name.
Qudian Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Qudian Inc. operates as a consumer-oriented technology company in the People's Republic of China. The company engages in the operation of online platforms to provide small consumer credit products. It also provides technology development and services; research and development services; and delivery services. The company was founded in 2014 and is headquartered in Xiamen, the People's Republic of China.
Issue price:
--